Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis has made a deal with PTC worth up to $2.9 billion for the development of a treatment for Huntington's disease. This agreement comes shortly after PTC discontinued another asset due to disappointing phase II data. Meanwhile, companies like Merck, Kazia Therapeutics, and others are focusing on developing treatments for glioblastoma, a deadly brain cancer, with new technologies and knowledge.In other news, Bluebird's gene therapy Skysona is under FDA safety probe for hematologic malignancies, while Applied Therapeutics faced a setback after the FDA rejected their drug for galactosemia. AstraZeneca/Daiichi Sankyo, BioNTech, and Merus are set to present promising cancer therapies at ESMO Asia 2024. The biopharma industry is seeing momentum in developing treatments for intractable and fatal diseases through the FDA's accelerated approval pathway.There have been layoffs at Idorsia Pharmaceuticals, and the use of digital twins is being explored to improve clinical research and address data disparities.